About Azidus Laboratories Limited
Data last updated: 18 December 2025
Azidus Laboratories Limited is a public limited company based in Chennai, Tamil Nadu, India. It specialises in biotechnology, a part of the broader life sciences sector. Incorporated on 22 July 1996, the company has been in operation for over 30 years.
Registered with ROC Chennai under CIN U24231TN1996PLC036136.
Capital: an authorised share capital of ₹25 Lakh and a paid-up capital of ₹25 Lakh. Formerly known as Omsoc Laboratories Limited. It is led by directors including Geethalakshmi and Olaganathan Arumugam Arjun.
Last AGM: 30 September 2024. Financial statements filed for year ended 31 March 2024. Office: 12A/2 Spartan Nagar Mugappair, Chennai, Tamil Nadu, India – 600037.
As per the financials filed for FY 2025, the company reported a revenue of ₹82.04 Cr, a decline of 10% compared to the previous year.
The company has a workforce of approximately 229 employees as per the latest available data.
The company is associated with 1 brand - Azidus.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website azidus.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered Address12A/2 Spartan Nagar Mugappair, Chennai, Tamil Nadu, India – 600037
-
IndustryLife Sciences, Biotechnology
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Azidus Laboratories Limited
Azidus Laboratories Limited has one previous CIN (Corporate Identification Number): L24231TN1996PLC036136. The current CIN is U24231TN1996PLC036136, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24231TN1996PLC036136 | Current |
| L24231TN1996PLC036136 | Previous |
Associated Brands with Azidus Laboratories Limited
Azidus Laboratories Limited operates one associated brand: Azidus. These brands represent Azidus Laboratories Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| A CRO providing BA/BE studies, clinical trials, data management, pharmacovigilance, and regulatory submissions. | azidus.com |
Competitors & Alternatives of Azidus Laboratories Limited
Brands and companies operating in the same space as Azidus Laboratories Limited include Emmes, Syneos Health, ClinChoice and 5 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Emmes
|
Outsourced contract research organization services are provided to clients. | United States | 1977 |
Syneos Health
|
CRO clinical development services are provided by Syneos Health. | Raleigh, United States, United States | 1984 |
ClinChoice
|
CRO focused on data management, regulatory affairs and consulting services | Fort Washington, United States, United States | 1995 |
Veristat
|
Clinical trials and regulatory submissions are supported as a CRO. | Southborough, United States, United States | 1994 |
Parexel
|
Full-service clinical research organization services are provided globally by Parexel. | Waltham, United States, United States | 1983 |
hVIVO
|
Provider of cell based assays, field trial, and molecular services for biopharma sector | London, United Kingdom, United Kingdom | 1998 |
Medelis WCCT Global
|
Full-service CRO expertise in influenza and oncology research is offered. | Cypress, United States, United States | 1998 |
Celgene
|
Therapies for cancer and inflammatory diseases are developed. | Summit, United States, United States | 1986 |
Business Activity of Azidus Laboratories Limited
Azidus Laboratories Limited is engaged in the principal business activity of professional, scientific and technical, with detailed activities including other professional, scientific and technical activities.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M9 | Other professional, scientific and technical activities | ********* |
Auditor Details of Azidus Laboratories Limited
Azidus Laboratories Limited is audited by A V DEVEN & CO. for the financial year 2024. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| A V DEVEN & CO. | blur-value | blur-value | blur-value |
Board of Directors of Azidus Laboratories Limited
Azidus Laboratories Limited is currently managed by 3 directors, with 6 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Geethalakshmi | Director | 01 Aug 2022 | 3 Years 11 Months | Current |
| Olaganathan Arumugam Arjun | Managing Director | 14 Dec 2011 | 14 Years 6 Months | Current |
|
Viswanathan Shanmugasundaram
Also directs:
Baddi Print Packs Private Limited, Kinesis Laboratories Private Limited, Flaring Formulations Private Limited and 5 more
|
Director | 01 Aug 2022 | 3 Years 11 Months | Current |
Financials of Azidus Laboratories Limited FY 2024 filings available
Azidus Laboratories Limited reported revenue of ₹82.04 Cr (down 10% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Azidus Laboratories Limited
As of FY 2024, Azidus Laboratories Limited's shareholding pattern shows 99.60% by promoters, 0.40% by public shareholders. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings Azidus Laboratories Limited
Azidus Laboratories Limited does not have any charges (loans) registered with the Registrar of Companies.
Employees and EPFO Compliance at Azidus Laboratories Limited
Azidus Laboratories Limited has a workforce of 229 employees as of Apr 06, 2024.
Employee Count & EPFO Data of Azidus Laboratories Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Azidus Laboratories Limited
GSTIN & GST Filing Data of Azidus Laboratories Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Azidus Laboratories Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Azidus Laboratories Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Azidus Laboratories Limited
MSME Payment Delays by Azidus Laboratories Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Azidus Laboratories Limited
Subsidiaries & Group Companies of Azidus Laboratories Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Azidus Laboratories Limited with ownership details.
MCA Filings & Documents of Azidus Laboratories Limited
MCA Filings & Documents of Azidus Laboratories Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Azidus Laboratories Limited
Frequently Asked Questions about Azidus Laboratories Limited
Azidus Laboratories Limited is an active public limited company in the life sciences sector based in Chennai, Tamil Nadu, India. It was incorporated on 22 July 1996 (30+ years old) and is registered under CIN U24231TN1996PLC036136. The company has 229 employees.
Azidus Laboratories Limited reported revenue of ₹82.04 Cr for FY 2025 (down 10.00% YoY).
The current directors of Azidus Laboratories Limited are:
The primary industry of Azidus Laboratories Limited is life sciences. The company specifically operates in biotechnology. The company is currently active in this sector.
Azidus Laboratories Limited can be reached at the registered office: 12A2 Spartan Nagar Mugappair, Chennai, Tamil Nadu, India – 600037, or through the website azidus.com.
The authorised capital is ₹25 Lakh, and the paid-up capital is ₹25 Lakh.